Grace Therapeutics, Inc., formerly known as Acasti Pharma Inc., has released its financial results for the year ended March 31, 2025. The company reported a net loss from operating activities of $16.679 million, a notable increase from the $12.852 million loss recorded in the previous year. Research and development expenses saw a significant rise to $9.511 million, up from $4.683 million the previous year. General and administrative expenses were reported at $7.168 million, compared to $6.684 million in the prior year. The company also reported a gain of $3.218 million from the change in fair value of derivative warrant liabilities, contrasting with a $2.728 million loss in the previous year. The report did not include specific guidance or outlook for future periods.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.